Pfizer/BioNTech's COVID-19 Vaccine Shows 100% Efficacy In Late-stage Trial In Adolescents

Pfizer/BioNTech's COVID-19 Vaccine Shows 100% Efficacy In Late-stage Trial In Adolescents

RTTNews

Published

Pfizer Inc. (PFE) and BioNTech's (BNTX) COVID-19 vaccine BNT162b2 has demonstrated 100% efficacy and robust antibody responses in a phase III trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the companies said in a statement.

Full Article